The National Comprehensive Cancer Network^® (NCCN^®) welcomes clinicians from teaching and community hospitals and academic centers in the general oncology community to submit patient case studies for the NCCN 2020 Annual Conference, scheduled to take place on March 20 – 22, 2020, at the Rosen Shingle Creek in Orlando, Florida.

To submit a patient case for consideration, please complete the following questionnaire. If you are submitting more than one case, please complete a separate questionnaire for each case. The deadline for submitting cases is Friday, January 10, 2020, at 11:59 PM EST (GMT 05:00).

Please answer the questions with as much detailed information as possible. Complete answers will assist us with the case selection process.

Submission Guidelines: There is no fee associated with submitting a case study, and you do not need to be registered to attend the conference to submit a case. You may submit more than one case for consideration. Please note that you may be asked to complete an NCCN Continuing Education Conflicts of Interest Form to disclose any relevant financial relationships from the past 12 months.

Selection Criteria: Cases will be evaluated and selected by the conference organizers. Cases should address current and relevant issues in oncology, prompt meaningful discussion questions, and demonstrate valuable teaching points.

Usage: Selected case studies will be presented and discussed by a panel of experts from NCCN Member Institutions during designated sessions at the conference. The cases may be modified to help facilitate the discussion. The cases also will be featured on the conference app and may be published on the NCCN Continuing Education Portal (education.nccn.org) after the conference. 

Recognition: All faculty for the conference have been confirmed. Case study contributors will be recognized in the conference materials, including the in-room slides, and verbally by the moderator at the beginning of each session.

NCCN will accept case study submissions in the following areas:

• Breast cancer
• Colorectal cancer
• Non-small cell lung cancer (non-squamous, metastatic disease)

Preference may be given to cases on the following topics: 

• Breast cancer
  • Early stage breast cancer: locoregional management in elderly patients
  • Early stage breast cancer: using gene expression assays for decision on adjuvant systemic therapy
  • HER2+ early stage breast cancer
  • Hormone-receptor-positive, HER2-negative metastatic breast cancer
  • Triple negative breast cancer
• Colorectal cancer
  • Metastatic colorectal cancer, BRAF V600E mutation-positive disease
  • Metastatic colorectal cancer with multiple actionable mutations/alterations (e.g., RAS wild-type and HER2-amplified, or other biomarker combinations)
  • Localized stage II or stage III colon cancer
  • Small bowel adenocarcinoma local or metastatic disease
• Non-small cell lung cancer (non-squamous, metastatic disease)
  • NSCLC, nonsquamous, metastatic with PD-L1 ≥50% and negative for EGFR, ALK, ROS1, BRAF
  • NSCLC, nonsquamous, metastatic with PD-L1 of 1-49% and negative for EGFR, ALK, ROS1, BRAF 
  • NSCLC, nonsquamous, metastatic with no testing for biomarkers